These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 19139740)
21. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Mathisen MS; Kantarjian H; Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; Borthakur G; Cortes JE; Quintás-Cardama A Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):139-43. PubMed ID: 23276886 [TBL] [Abstract][Full Text] [Related]
22. Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia. Moreno L; Fernandez-Navarro JM; Del Mar Andres M; Bautista F; Tasso M; Verdeguer A J Pediatr Hematol Oncol; 2012 Jan; 34(1):e17-21. PubMed ID: 21716139 [TBL] [Abstract][Full Text] [Related]
23. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. Chemnitz JM; von Lilienfeld-Toal M; Holtick U; Theurich S; Shimabukuro-Vornhagen A; Krause A; Brossart P; Hallek M; Scheid C Ann Hematol; 2012 Jan; 91(1):47-55. PubMed ID: 21584670 [TBL] [Abstract][Full Text] [Related]
24. Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Chevallier P; Labopin M; Buchholz S; Ganser A; Ciceri F; Lioure B; Faul C; Guillerm G; Finke J; Huynh A; Schubert J; Kolb HJ; Polge E; Nagler A; Mohty M Eur J Haematol; 2012 Sep; 89(3):214-9. PubMed ID: 22702414 [TBL] [Abstract][Full Text] [Related]
25. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Devillier R; Crocchiolo R; Castagna L; Fürst S; El Cheikh J; Faucher C; Prebet T; Etienne A; Chabannon C; Vey N; Esterni B; Blaise D Bone Marrow Transplant; 2012 May; 47(5):639-45. PubMed ID: 22307016 [TBL] [Abstract][Full Text] [Related]
26. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Faderl S; Ravandi F; Huang X; Garcia-Manero G; Ferrajoli A; Estrov Z; Borthakur G; Verstovsek S; Thomas DA; Kwari M; Kantarjian HM Blood; 2008 Sep; 112(5):1638-45. PubMed ID: 18565853 [TBL] [Abstract][Full Text] [Related]
27. Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS. Chevallier P; Labopin M; de La Tour RP; Lioure B; Bulabois CE; Huynh A; Blaise D; Turlure P; Daguindau E; Maillard N; Yakoub-Agha I; Guillerm G; Delage J; Contentin N; Bay JO; Beckerich F; Bourhis JH; Detrait M; Vigouroux S; François S; Legrand F; Guillaume T; Mohty M; Cancer Med; 2016 Nov; 5(11):3068-3076. PubMed ID: 27748046 [TBL] [Abstract][Full Text] [Related]
28. Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. Shimoni A; Shem-Tov N; Volchek Y; Danylesko I; Yerushalmi R; Nagler A Bone Marrow Transplant; 2012 Oct; 47(10):1274-82. PubMed ID: 22327135 [TBL] [Abstract][Full Text] [Related]
29. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia. Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926 [TBL] [Abstract][Full Text] [Related]